Oncosynergy is a UCSF spinout with primary operations in JLABS @ SSF, California. The company was founded in 2011 to provide solutions for treatment-resistant cancer through the development of a new class of oncology therapeutics, called Resistance Mechanism Inhibitors (RMIs). RMIs are unique multi-action, tumor-agnostic drug platforms that have shown preclinical promise as monotherapy and in strategic combinations.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/04/18 | undisclosed | Series A |
Connecticut Innovations Korea Information & Communication Co. NLabs | undisclosed |
